Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plasma Exchange | 4 | 2019 | 20 | 1.860 |
Why?
|
| Hypocalcemia | 5 | 2019 | 16 | 1.600 |
Why?
|
| Calcium Gluconate | 2 | 2019 | 5 | 1.300 |
Why?
|
| Calcium | 5 | 2019 | 550 | 0.900 |
Why?
|
| Blood Component Removal | 2 | 2019 | 11 | 0.700 |
Why?
|
| Renal Dialysis | 1 | 2016 | 184 | 0.480 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 1999 | 8 | 0.420 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 1999 | 72 | 0.410 |
Why?
|
| Babesia microti | 1 | 2009 | 5 | 0.340 |
Why?
|
| Babesiosis | 1 | 2009 | 10 | 0.340 |
Why?
|
| Transfusion Reaction | 1 | 2009 | 46 | 0.330 |
Why?
|
| Erythrocytes | 1 | 2009 | 153 | 0.320 |
Why?
|
| Infusions, Intravenous | 2 | 2019 | 170 | 0.310 |
Why?
|
| Premedication | 2 | 2018 | 17 | 0.300 |
Why?
|
| Gene Expression | 4 | 1999 | 805 | 0.250 |
Why?
|
| Erythrocyte Transfusion | 2 | 2018 | 75 | 0.240 |
Why?
|
| Endometrium | 2 | 1999 | 28 | 0.200 |
Why?
|
| Citric Acid | 2 | 2018 | 10 | 0.190 |
Why?
|
| Plateletpheresis | 2 | 2017 | 4 | 0.180 |
Why?
|
| Blood Donors | 2 | 2017 | 21 | 0.180 |
Why?
|
| Catheters, Indwelling | 1 | 2019 | 63 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2019 | 98 | 0.160 |
Why?
|
| RNA, Messenger | 5 | 1999 | 1461 | 0.160 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 85 | 0.160 |
Why?
|
| Fallopian Tubes | 2 | 1994 | 12 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 65 | 0.150 |
Why?
|
| Citrates | 1 | 2017 | 15 | 0.150 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2017 | 10 | 0.150 |
Why?
|
| Cathepsin D | 2 | 1996 | 11 | 0.140 |
Why?
|
| Cholecalciferol | 1 | 2017 | 26 | 0.140 |
Why?
|
| RNA, Neoplasm | 2 | 1996 | 34 | 0.140 |
Why?
|
| Humans | 17 | 2019 | 59008 | 0.140 |
Why?
|
| Leukapheresis | 1 | 2016 | 7 | 0.140 |
Why?
|
| In Situ Hybridization | 5 | 1999 | 215 | 0.140 |
Why?
|
| Serum Albumin, Human | 1 | 2016 | 6 | 0.140 |
Why?
|
| Glucose | 1 | 2018 | 440 | 0.120 |
Why?
|
| Ovary | 1 | 1995 | 96 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 257 | 0.120 |
Why?
|
| Middle Aged | 4 | 2019 | 16184 | 0.120 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1993 | 104 | 0.110 |
Why?
|
| Mannosephosphates | 1 | 1993 | 2 | 0.110 |
Why?
|
| Receptor, IGF Type 2 | 1 | 1993 | 3 | 0.110 |
Why?
|
| Delaware | 2 | 2011 | 6 | 0.110 |
Why?
|
| Female | 11 | 2019 | 30662 | 0.110 |
Why?
|
| Anemia, Neonatal | 1 | 2011 | 3 | 0.090 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2011 | 16 | 0.090 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2011 | 35 | 0.090 |
Why?
|
| Infant, Premature, Diseases | 1 | 2011 | 46 | 0.090 |
Why?
|
| Hepatitis, Chronic | 1 | 1990 | 6 | 0.090 |
Why?
|
| Hepatitis B | 1 | 1990 | 28 | 0.090 |
Why?
|
| RNA | 1 | 1993 | 400 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2009 | 111 | 0.080 |
Why?
|
| DNA, Viral | 1 | 1990 | 228 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2019 | 5129 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 1996 | 1118 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 894 | 0.070 |
Why?
|
| Factor XI | 1 | 2005 | 2 | 0.060 |
Why?
|
| Factor IX | 1 | 2005 | 7 | 0.060 |
Why?
|
| Plasminogen | 1 | 2005 | 7 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 1995 | 498 | 0.060 |
Why?
|
| RNA-Directed DNA Polymerase | 2 | 1995 | 22 | 0.060 |
Why?
|
| Peptide Hydrolases | 1 | 2005 | 77 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 1995 | 846 | 0.060 |
Why?
|
| Male | 4 | 2019 | 27369 | 0.060 |
Why?
|
| Adult | 3 | 2009 | 15659 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2018 | 3 | 0.040 |
Why?
|
| Iron Overload | 1 | 2018 | 4 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 7 | 0.040 |
Why?
|
| DNA Restriction Enzymes | 2 | 1994 | 35 | 0.040 |
Why?
|
| Calcium Phosphates | 1 | 2017 | 8 | 0.040 |
Why?
|
| Citrus | 1 | 2017 | 37 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 190 | 0.040 |
Why?
|
| Breast Diseases | 2 | 1996 | 39 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 219 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1996 | 22 | 0.030 |
Why?
|
| Theca Cells | 1 | 1995 | 1 | 0.030 |
Why?
|
| Luteal Cells | 1 | 1995 | 2 | 0.030 |
Why?
|
| Granulosa Cells | 1 | 1995 | 15 | 0.030 |
Why?
|
| Luteal Phase | 1 | 1995 | 27 | 0.030 |
Why?
|
| Pregnancy, Ectopic | 1 | 1995 | 12 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2017 | 176 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2017 | 243 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 1994 | 28 | 0.030 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1994 | 16 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1054 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1994 | 52 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 701 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 1994 | 110 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1994 | 162 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1996 | 438 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 321 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 1993 | 124 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 3078 | 0.020 |
Why?
|
| Pregnancy | 2 | 1995 | 2334 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1995 | 864 | 0.020 |
Why?
|
| Hepatitis B Core Antigens | 1 | 1990 | 4 | 0.020 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1990 | 16 | 0.020 |
Why?
|
| Menopause | 1 | 1993 | 246 | 0.020 |
Why?
|
| Hepatitis B virus | 1 | 1990 | 13 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 147 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2011 | 73 | 0.020 |
Why?
|
| Gestational Age | 1 | 2011 | 181 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3552 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 770 | 0.020 |
Why?
|
| Virus Replication | 1 | 1990 | 297 | 0.020 |
Why?
|
| DNA Replication | 1 | 1990 | 229 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 1304 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7458 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 1 | 2005 | 53 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 2429 | 0.020 |
Why?
|
| Longevity | 1 | 2005 | 111 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 2449 | 0.010 |
Why?
|
| Aged | 1 | 1999 | 13259 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 4983 | 0.010 |
Why?
|
| Lung | 1 | 2005 | 818 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 1984 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 5949 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 1096 | 0.010 |
Why?
|
| Cryoultramicrotomy | 1 | 1996 | 1 | 0.010 |
Why?
|
| Matrix Metalloproteinase 11 | 1 | 1996 | 1 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 1996 | 7 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1996 | 130 | 0.010 |
Why?
|
| Isomerism | 1 | 1994 | 27 | 0.010 |
Why?
|
| Thymidine | 1 | 1994 | 25 | 0.010 |
Why?
|
| Autoradiography | 1 | 1994 | 53 | 0.010 |
Why?
|
| Stromal Cells | 1 | 1994 | 65 | 0.010 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 1994 | 28 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1994 | 220 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1994 | 139 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1994 | 130 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1994 | 171 | 0.010 |
Why?
|
| Cell Division | 1 | 1994 | 441 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1994 | 145 | 0.010 |
Why?
|
| Mice | 1 | 2005 | 10220 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1994 | 2090 | 0.010 |
Why?
|
| Proteins | 1 | 1994 | 742 | 0.000 |
Why?
|
| Animals | 1 | 2005 | 19531 | 0.000 |
Why?
|